SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
KRYS

Krystal Biotech, Inc. (NASDAQ:KRYS)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$308.89-$6.93 (-2.19%)
 
Market cap
$9.15B
Insider Score
Analyst consensus
Listed since
Sep 20, 2017
Market Cap$9.15B+43.7%
Revenue (ttm)n/a+26.0%
Net Incomen/a+13.2%
EPSn/a+10.5%
Shares Out29.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume286,698
Open$316.20
Previous Close$315.82
Day's Range$308.24 - $320.70
52-Week Range$212.02 - $382.54
Beta0.50
AnalystsBuy
Price Target$418.40(+35.45%)
Earnings Daten/a

About KRYS

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Address
2100 Wharton Street, Pittsburgh, PA, 15203, US
Market Cap
9.15 billion
Employees
295
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$17.97M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
5 Buy0 Hold0 SellAvg target $379.20 (+22.8%)

5 firms rating KRYS in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-2.19%
5 Days
+1.99%
1 Month
-3.51%
6 Months
+3.15%
1 Year
+43.74%

$KRYS stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in KRYS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by KRYS's directors and management

Net Shares Purchased by Insiders−50k−25k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

KRYS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

KRYS Revenue by Segment

$136.34MTotal
Product revenue, net$127.34M93.40%
Interest and other income, net$9.00M6.60%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New KRYS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to KRYS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in KRYS

IJHiShares Core S&P Mid-Cap ETF$303.17M
VTIVanguard Morningstar Total Stock Market ETF$222.52M
IWMiShares Russell 2000 ETF$215.78M
VBVanguard Morningstar Small-Cap ETF$198.46M
XBIState Street SPDR S&P Biotech ETF$137.42M
VBKVanguard Morningstar Small-Cap Growth ETF$111.10M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from KRYS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
26
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-36.0 since Aug 21
0255075100Aug 21 — Insider Score 36.0Aug 22 — Insider Score 36.0Aug 23 — Insider Score 36.0Aug 24 — Insider Score 36.0Aug 25 — Insider Score 36.0Aug 26 — Insider Score 36.0Aug 27 — Insider Score 37.0Aug 28 — Insider Score 37.0Aug 29 — Insider Score 37.0Aug 30 — Insider Score 37.0Aug 31 — Insider Score 37.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 25.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

HELXFranklin Genomic Advancements ETF4.88%
XOVRERShares Private-Public Crossover ETF1.79%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF1.75%
WDNAWisdomTree BioRevolution Fund1.42%
CSMDCongress SMID Growth ETF1.41%
RFGInvesco S&P MidCap 400 Pure Growth ETF1.35%
XBIState Street SPDR S&P Biotech ETF1.31%
GURUGlobal X - Guru Index ETF1.28%
XMMOInvesco S&P MidCap Momentum ETF1.25%
BBPVirtus Biotech ETF1.25%
SLTPacer Salt High truBeta US Market ETF1.17%
LSLTPacer Salt Low truBeta US Market ETF1.17%

Weight is the stock’s share of each fund’s holdings.